Elevance Health (NYSE:ELV) today reported fourth-quarter and full-year 2025 results that showcased robust top-line growth, even as the company manages shifting dynamics in its Medicaid and Medicare Advantage businesses.
The health insurer posted full-year operating revenue of $197.6 billion, a significant climb from the prior year, driven by premium yields and the continued scaling of its Carelon health services brand.
For the fourth quarter ended Dec. 31, 2025, Elevance reported operating revenue of $49.3 billion.
Diluted earnings per share (EPS) stood at $2.47, while adjusted diluted EPS reached $3.33.
On a full-year basis, the company delivered a GAAP EPS of $25.21 and an adjusted EPS of $30.29, meeting the updated targets set earlier in the fiscal year.
Following the quarter performance, the company provided a pragmatic outlook for 2026, projecting GAAP diluted EPS to be at least $22.30 and adjusted diluted EPS to be at least $25.50.